Gianpiero Fasola

PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type <i>KRAS</i> Exon 2 Metastatic Colorectal Cancer

Lee S. Schwartzberg, Fernando Rivera, Meinolf Karthaus et al. · Journal of Clinical Oncology · 2014 · 623 citations

Measures of Outcome in Metastatic Breast Cancer: Insights From a Real-World Scenario

Marta Bonotto, Lorenzo Gerratana, Elena Poletto et al. · The Oncologist · 2014 · 283 citations · Full text

Pattern of metastasis and outcome in patients with breast cancer

Lorenzo Gerratana, V. Fanotto, Marta Bonotto et al. · Clinical & Experimental Metastasis · 2015 · 212 citations

Surgical Oncology, Breast Oncology, Medicine +6

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

Marta Schirripa, Francesca Bergamo, Chiara Cremolini et al. · British Journal of Cancer · 2015 · 168 citations · Full text

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht et al. · International Journal of Colorectal Disease · 2017 · 132 citations · Full text